NASDAQ:CGNT - Vision Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$3.85
Today's Range$3.85 - $3.85
52-Week Range$1.55 - $3.92
VolumeN/A
Average Volume183,912 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes. In addition, the company offers Urgent PC System, a neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder; and Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. Further, it provides Macroplastique products for the treatment of vesicoureteral reflux; PTQ Implants to treat fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants to enhance speech and swallowing function in patients with unilateral vocal cord paralysis. Additionally, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical, Inc. sells its products through a direct sales force and a network of distributor organizations. The company was founded in 1987 and is headquartered in Minnetonka, Minnesota.

Receive CGNT News and Ratings via Email

Sign-up to receive the latest news and ratings for CGNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGNT
Previous Symbol
CUSIPN/A
Phone952-426-6140

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees208
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Vision Sciences (NASDAQ:CGNT) Frequently Asked Questions

What is Vision Sciences' stock symbol?

Vision Sciences trades on the NASDAQ under the ticker symbol "CGNT."

How were Vision Sciences' earnings last quarter?

Vision Sciences Inc. (NASDAQ:CGNT) announced its quarterly earnings data on Tuesday, November, 3rd. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The medical device company earned $11.80 million during the quarter, compared to analysts' expectations of $11.45 million. View Vision Sciences' Earnings History.

What price target have analysts set for CGNT?

2 analysts have issued twelve-month price objectives for Vision Sciences' shares. Their forecasts range from $4.00 to $4.75. On average, they expect Vision Sciences' share price to reach $4.3750 in the next twelve months. View Analyst Price Targets for Vision Sciences.

What is the consensus analysts' recommendation for Vision Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vision Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vision Sciences.

Has Vision Sciences been receiving favorable news coverage?

Press coverage about CGNT stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vision Sciences earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Vision Sciences' key competitors?

Who are Vision Sciences' key executives?

Vision Sciences' management team includes the folowing people:
  • Mr. Darin Hammers, Pres, CEO & Director (Age 53)
  • Mr. Brett A. Reynolds, Sr. VP, CFO & Corp. Sec. (Age 49)
  • Mr. Chris Arnold, VP of Global Sales (Age 50)
  • Mr. Larry Heinemann, VP of Corp. Devel. (Age 66)
  • Mr. Ash Keswani, Sr. VP of Marketing & Bus. Devel.

How do I buy shares of Vision Sciences?

Shares of CGNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vision Sciences' official website?

The official website for Vision Sciences is http://www.cogentixmedical.com.

How can I contact Vision Sciences?

Vision Sciences' mailing address is 5420 FELTL ROAD, MINNETONKA MN, 55343. The medical device company can be reached via phone at 952-426-6140 or via email at [email protected]


MarketBeat Community Rating for Vision Sciences (NASDAQ CGNT)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Vision Sciences and other stocks. Vote "Outperform" if you believe CGNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel